Maxim Group Sticks to Their Buy Rating for Plus Therapeutics (PSTV)
at www.tipranks.com (Fri, 23-Jan 9:36 AM)
Plus Therapeutics: Underpenetrated CNSide Commercial Potential and Reyobiq Accelerated-Approval Upside Support Buy Rating into 2026
at www.tipranks.com (Fri, 23-Jan 6:15 AM)
Plus Therapeutics Sharpens Focus on CNS Cancer Strategy
at www.tipranks.com (Thu, 22-Jan 8:09 AM)
